Browse VEGFC

Summary
SymbolVEGFC
Namevascular endothelial growth factor C
Aliases vascular endothelial growth factor-related protein; Flt4-L; LMPH1D; FLT4 ligand DHM; Flt4 ligand; VEGF-C
Chromosomal Location4q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF03128 CXCXC repeat
PF00341 PDGF/VEGF domain
Function

Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001666 response to hypoxia
GO:0001667 ameboidal-type cell migration
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0001945 lymph vessel development
GO:0001946 lymphangiogenesis
GO:0001952 regulation of cell-matrix adhesion
GO:0001954 positive regulation of cell-matrix adhesion
GO:0002052 positive regulation of neuroblast proliferation
GO:0002551 mast cell chemotaxis
GO:0002576 platelet degranulation
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0003013 circulatory system process
GO:0006887 exocytosis
GO:0006929 substrate-dependent cell migration
GO:0007160 cell-matrix adhesion
GO:0007405 neuroblast proliferation
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0009306 protein secretion
GO:0010594 regulation of endothelial cell migration
GO:0010595 positive regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0010720 positive regulation of cell development
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0016331 morphogenesis of embryonic epithelium
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0030335 positive regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0030947 regulation of vascular endothelial growth factor receptor signaling pathway
GO:0031589 cell-substrate adhesion
GO:0031952 regulation of protein autophosphorylation
GO:0031954 positive regulation of protein autophosphorylation
GO:0032103 positive regulation of response to external stimulus
GO:0036293 response to decreased oxygen levels
GO:0036303 lymph vessel morphogenesis
GO:0040017 positive regulation of locomotion
GO:0042493 response to drug
GO:0043534 blood vessel endothelial cell migration
GO:0043535 regulation of blood vessel endothelial cell migration
GO:0043536 positive regulation of blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0045055 regulated exocytosis
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045776 negative regulation of blood pressure
GO:0045785 positive regulation of cell adhesion
GO:0046777 protein autophosphorylation
GO:0048010 vascular endothelial growth factor receptor signaling pathway
GO:0048514 blood vessel morphogenesis
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050769 positive regulation of neurogenesis
GO:0050900 leukocyte migration
GO:0050918 positive chemotaxis
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0050926 regulation of positive chemotaxis
GO:0050927 positive regulation of positive chemotaxis
GO:0050930 induction of positive chemotaxis
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0051272 positive regulation of cellular component movement
GO:0051302 regulation of cell division
GO:0051781 positive regulation of cell division
GO:0051962 positive regulation of nervous system development
GO:0060326 cell chemotaxis
GO:0060753 regulation of mast cell chemotaxis
GO:0060754 positive regulation of mast cell chemotaxis
GO:0061351 neural precursor cell proliferation
GO:0070482 response to oxygen levels
GO:0072089 stem cell proliferation
GO:0072091 regulation of stem cell proliferation
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0097529 myeloid leukocyte migration
GO:0097531 mast cell migration
GO:1901342 regulation of vasculature development
GO:1901490 regulation of lymphangiogenesis
GO:1901492 positive regulation of lymphangiogenesis
GO:1902692 regulation of neuroblast proliferation
GO:1903532 positive regulation of secretion by cell
GO:1904018 positive regulation of vasculature development
GO:1904951 positive regulation of establishment of protein localization
GO:2000147 positive regulation of cell motility
GO:2000177 regulation of neural precursor cell proliferation
GO:2000179 positive regulation of neural precursor cell proliferation
GO:2000648 positive regulation of stem cell proliferation
Molecular Function GO:0005126 cytokine receptor binding
GO:0005172 vascular endothelial growth factor receptor binding
GO:0008083 growth factor activity
GO:0042056 chemoattractant activity
GO:0043185 vascular endothelial growth factor receptor 3 binding
GO:0070851 growth factor receptor binding
Cellular Component GO:0030141 secretory granule
GO:0031091 platelet alpha granule
GO:0031093 platelet alpha granule lumen
GO:0031983 vesicle lumen
GO:0034774 secretory granule lumen
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04668 TNF signaling pathway
Reactome R-HSA-109582: Hemostasis
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-162582: Signal Transduction
R-HSA-194138: Signaling by VEGF
R-HSA-195399: VEGF binds to VEGFR leading to receptor dimerization
R-HSA-194313: VEGF ligand-receptor interactions
Summary
SymbolVEGFC
Namevascular endothelial growth factor C
Aliases vascular endothelial growth factor-related protein; Flt4-L; LMPH1D; FLT4 ligand DHM; Flt4 ligand; VEGF-C
Chromosomal Location4q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between VEGFC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between VEGFC and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28904226MelanomaPromote immunityIn human metastatic melanoma, gene expression of VEGF-C strongly correlated with CCL21 and T cell inflammation, and serum VEGF-C concentrations associated with both T cell activation and expansion after peptide vaccination and clinical response to checkpoint blockade. We propose that VEGF-C potentiates immunotherapy by attracting naïve T cells, which are locally activated upon immunotherapy-induced tumor cell killing, and that serum VEGF-C may serve as a predictive biomarker for immunotherapy response.
Summary
SymbolVEGFC
Namevascular endothelial growth factor C
Aliases vascular endothelial growth factor-related protein; Flt4-L; LMPH1D; FLT4 ligand DHM; Flt4 ligand; VEGF-C
Chromosomal Location4q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of VEGFC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolVEGFC
Namevascular endothelial growth factor C
Aliases vascular endothelial growth factor-related protein; Flt4-L; LMPH1D; FLT4 ligand DHM; Flt4 ligand; VEGF-C
Chromosomal Location4q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of VEGFC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8840.0356
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5160.625
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.1440.113
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5760.201
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.350.804
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8550.649
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2780.554
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2640.773
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2610.799
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3310.266
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9660.243
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1120.461
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of VEGFC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277309.6-9.60.185
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014014.3-14.31
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275908.5-8.50.32
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolVEGFC
Namevascular endothelial growth factor C
Aliases vascular endothelial growth factor-related protein; Flt4-L; LMPH1D; FLT4 ligand DHM; Flt4 ligand; VEGF-C
Chromosomal Location4q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of VEGFC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolVEGFC
Namevascular endothelial growth factor C
Aliases vascular endothelial growth factor-related protein; Flt4-L; LMPH1D; FLT4 ligand DHM; Flt4 ligand; VEGF-C
Chromosomal Location4q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of VEGFC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by VEGFC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolVEGFC
Namevascular endothelial growth factor C
Aliases vascular endothelial growth factor-related protein; Flt4-L; LMPH1D; FLT4 ligand DHM; Flt4 ligand; VEGF-C
Chromosomal Location4q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of VEGFC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolVEGFC
Namevascular endothelial growth factor C
Aliases vascular endothelial growth factor-related protein; Flt4-L; LMPH1D; FLT4 ligand DHM; Flt4 ligand; VEGF-C
Chromosomal Location4q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of VEGFC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolVEGFC
Namevascular endothelial growth factor C
Aliases vascular endothelial growth factor-related protein; Flt4-L; LMPH1D; FLT4 ligand DHM; Flt4 ligand; VEGF-C
Chromosomal Location4q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between VEGFC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolVEGFC
Namevascular endothelial growth factor C
Aliases vascular endothelial growth factor-related protein; Flt4-L; LMPH1D; FLT4 ligand DHM; Flt4 ligand; VEGF-C
Chromosomal Location4q34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting VEGFC collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.